Stock 2137 BRII BIOSCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Brii Biosciences Limited

Equities

2137

KYG1645A1094

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
1.09 HKD +9.00% Intraday chart for Brii Biosciences Limited +18.48% -52.19%
Mar. 25 Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
Mar. 22 Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
AQ
Transcript : Brii Biosciences Limited, 2023 Earnings Call, Mar 25, 2024
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179
AQ
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences
MT
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI
MT
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
PR
Transcript : Brii Biosciences Limited - Special Call
Brii Biosciences Hires Chief Scientific Officer
MT
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
PR
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
CI
Brii Biosciences Presents Hepatitis B Treatment Data at US Liver Disease Conference
MT
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023
CI
Transcript : Brii Biosciences Limited - Special Call
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 in Combination with PEG-IFN for the Treatment of Chronic Hepatitis B
AQ
Brii Biosciences’ Study Into Therapeutic Vaccine for Chronic Hepatitis B Patients Shows Safety, Tolerability
MT
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
PR
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B
CI
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179
CI
Transcript : Brii Biosciences Limited - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2137 Stock
  4. News Brii Biosciences Limited